EnVVeno Medical Reports Interim Venous Ulcer Healing Data From SAVVE U.E. Pivotal Trial For VenoValve To Be Presented At Society For Vascular Surgery 2024 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
EnVVeno Medical reported positive interim data from its SAVVE U.E. pivotal trial for the VenoValve, showing significant healing in venous ulcer patients. The company plans to seek FDA approval in Q4 2024.
June 21, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EnVVeno Medical's VenoValve has shown promising interim results in healing venous ulcers, with a high percentage of patients experiencing full healing or improvement. The company is on track to file for FDA approval in Q4 2024.
The positive interim results from the SAVVE U.E. pivotal trial indicate strong efficacy of the VenoValve, which is likely to boost investor confidence. The upcoming FDA approval filing in Q4 2024 adds a significant regulatory milestone that could further impact the stock positively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100